RCM
CAPR icon

RA Capital Management’s Capricor Therapeutics CAPR Stock Holding History

RA Capital Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.8M Hold
1,507,844
– – 0.49% 38
2025
Q4 		$43.5M Buy
+1,507,844
New +$19.7M 0.45% 38

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RA Capital Management's CAPR Position: Q1 2026 in Review

RA Capital Management held its Capricor Therapeutics (CAPR) position steady in Q1 2026 at 1,507,844 shares worth $45.8M. The position accounts for 0.49% of the portfolio, ranked #38.

RA Capital Management first reported a position in CAPR in Q4 2025 and has held it in 2 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • RA Capital Management held 1,507,844 shares of Capricor Therapeutics worth $45.8M as of Q1 2026.
  • RA Capital Management left its Capricor Therapeutics share count unchanged in Q1 2026.
  • Capricor Therapeutics made up 0.49% of RA Capital Management's portfolio in Q1 2026, its #38 holding.
  • RA Capital Management first reported a position in Capricor Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.